Join us in revolutionizing chronic pain treatment with proven, non-opioid solutions that address a critical, underserved market.
Alyea Therapeutics is poised to redefine chronic pain treatment with its innovative non-opioid solutions. With LDN progressing through regulatory approval and the Alyea Clear Patch technology expanding market opportunities, the company is at a pivotal stage for growth.
Investors have a unique opportunity to support a breakthrough approach to pain management that addresses a critical, underserved market.
Dr. Soin is a nationally recognized thought leader and innovator in pain management, dedicated to advancing safe, non-opioid solutions for chronic pain. He has served as President of the American Society of Interventional Pain Physicians and several other national and state organizations, helping shape clinical standards and policy. Dr. Soin holds five academic degrees–including from Dartmouth and Brown–and has authored a medical textbook and more than 100 peer-reviewed publications. He holds several dozen global patents for medical devices and pharmaceutical compounds aimed at breaking the cycle of opioid dependence. A former President of the Ohio Medical Board, Dr. Soin played a key role in passing statewide opioid regulations. His leadership continues to drive Alyea’s mission to redefine pain care through innovation and compassion.
Tony brings over 30 years of leadership in biotechnology, drug development, and translational science. He has held executive roles across multiple life sciences companies, where he successfully advanced therapies from early-stage discovery into clinical trials. With more than 20 U.S. patents, Tony work spans neurodegenerative diseases, oncology, and cardiovascular health. He has a strong track record of securing funding and building research-driven organizations. Prior to joining us, he served as President and CEO of NeuroTherapia and Abcon Therapeutics. Tony holds a Ph.D. in Molecular Genetics from The Ohio State University.
Russ Belden brings over 37 years of biotech commercialization and operational leadership experience, with a focus on guiding emerging biotech companies from preclinical stages to first launch. He began his career at Genentech, where he played a pivotal role in launching their BioOncology franchise–including Rituxan and Herceptin–and rose to become Director of Hematology Sales. As Founder and CEO of Bridge, Russ has supported more than 125 early-stage biotech companies, delivering hands-on commercialization strategy and interim leadership. He is also a recognized educator, having co-developed industry courses on drug valuation and commercialization readiness. Russ holds a B.S. in Pharmacy from the University of New York at Buffalo.
LDN is a non-opioid treatment that works by modulating pain pathways and reducing inflammation rather than masking symptoms. Unlike opioids, it has no risk of addiction or dependence and provides long-term relief without severe side effects.
LDN has received FDA orphan drug designation for the treatment of Complex Regional Pain Syndrome (CRPS) and is currently advancing through clinical trials toward full regulatory approval. LDN is NOT FDA approved and Alyea’s version is still investigational and in clinical trials.
Alyea Clear Patch is a topical pain relief technology designed for targeted, localized treatment. It delivers non-invasive pain relief that is customizable to the location of pain. It allows for localized treatments without a lot of systemic absorption.
Alyea’s solutions are designed for patients suffering from chronic pain conditions such as CRPS for LDN and other inflammatory pain disorders for the clear patch, especially those seeking non-opioid alternatives.
Invest in innovative, non-opioid treatments that address a critical, underserved market.
Get In Touch
